Human Immunodeficiency Virus Rebound after Suppression to <400 Copies/mL during Initial Highly Active Antiretroviral Therapy Regimens, according to Prior Nucleoside Experience and Duration of Suppression

This study evaluated 1433 human immunodeficiency virus (HIV)–infected patients starting highly active antiretroviral therapy (HAART), 409 (28%) of whom had prior nucleoside experience and achieved an HIV load of

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2002-10, Vol.186 (8), p.1086-1091
Main Authors: Phillips, Andrew N., Staszewski, Schlomo, Lampe, Fiona, Youle, Michael S., Klauke, Stephan, Bickel, Markus, Sabin, Caroline A., Doerr, Hans Wilhelm, Johnson, Margaret A., Loveday, Clive, Miller, Veronica
Format: Article
Language:English
Subjects:
Adult
AIDS
Anti-HIV Agents - administration & dosage
Anti-HIV Agents - therapeutic use
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiretroviral Therapy, Highly Active
Antiretrovirals
Antiviral agents
Antivirals
Biological and medical sciences
CD4 Lymphocyte Count
Disease Progression
Drug Resistance, Viral
Female
Highly active antiretroviral therapy
HIV
HIV - drug effects
HIV - genetics
HIV - growth & development
HIV 1
HIV Infections - drug therapy
HIV Infections - virology
Humans
Major Articles
Male
Medical sciences
Nucleosides
Pharmacology. Drug treatments
RNA
RNA, Viral - blood
Time Factors
Treatment Failure
Viral Load
Virology
Viruses
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study evaluated 1433 human immunodeficiency virus (HIV)–infected patients starting highly active antiretroviral therapy (HAART), 409 (28%) of whom had prior nucleoside experience and achieved an HIV load of
ISSN:0022-1899
1537-6613
DOI:10.1086/343801